Asif Ahmed (scientist): Difference between revisions
Pro-wiki99 (talk | contribs) No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
| alma_mater = [[King's College London]]<br>[[University College London]] |
| alma_mater = [[King's College London]]<br>[[University College London]] |
||
}} |
}} |
||
'''Asif Ahmed''' [[FRSB]] (born 1st June 1960) is a British vascular and obstetric scientist and an entrepreneur<ref>{{Cite web|url=http://www.birminghampost.co.uk/business/business-news/aston-universitys-new-60m-medical-7255020|title=Birmingham Post|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. He is responsible for founding [[Aston Medical School]], the second medical school to be established in the city of [[Birmingham]] after 200 years. Aston Medical School has [[social mobility]] and leadership at the core of its model without compromising entry standards.<ref>http://www.aston.ac.uk/aston-medical-school/</ref> Ahmed's discoveries and his disrupitve approach have led to new clinical trials designed to treat the deadliest maternal hypertensive disorder, [[Pre-eclampsia|preeclampsia]]. He has a longstanding interest in the mechanisms of [[vascular endothelial growth factor]] signalling, [[Endothelium|endothelial cell]] protection and has developed new strategies for preventing preeclampsia<ref>{{ |
'''Asif Ahmed''' [[FRSB]] (born 1st June 1960) is a British vascular and obstetric scientist and an entrepreneur<ref>{{Cite web|url=http://www.birminghampost.co.uk/business/business-news/aston-universitys-new-60m-medical-7255020|title=Birmingham Post|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. He is responsible for founding [[Aston Medical School]], the second medical school to be established in the city of [[Birmingham]] after 200 years. Aston Medical School has [[social mobility]] and leadership at the core of its model without compromising entry standards.<ref>http://www.aston.ac.uk/aston-medical-school/</ref> Ahmed's discoveries and his disrupitve approach have led to new clinical trials designed to treat the deadliest maternal hypertensive disorder, [[Pre-eclampsia|preeclampsia]]. He has a longstanding interest in the mechanisms of [[vascular endothelial growth factor]] signalling, [[Endothelium|endothelial cell]] protection and has developed new strategies for preventing preeclampsia.<ref>{{cite journal |pmid=27873232 }}</ref> He is widely recognized as the first person to propose and initiate the first clinical trial on [[Statin|statins]] to ameliorate sever preeclampsia.<ref>{{cite journal |doi=10.1186/ISRCTN23410175 }}</ref> |
||
Ahmed is the inaugural Executive Dean of Aston Medical School and Pro-Vice-Chancellor at [[Aston University]]. He holds the Chair of Vascular Biology and the 50th Anniversary Chair of [[Translational medicine|Translational Medicine]]. In addition, he is the KAU Distinguished Adjunct Professor at [[King Abdulaziz University|King AbdulAziz University]] and an Honorary Professor at the [[Jilin University|Jilin University Hospital]]. His main area of research is [[Angiogenesis|preeclampsia, angiogenesis]] and [[gaseous signalling molecules]]. In addition, Professor Ahmed established and leads the Aston Medical Research Institute, a university-wide multidisciplinary translational research entity at Aston University. |
Ahmed is the inaugural Executive Dean of Aston Medical School and Pro-Vice-Chancellor at [[Aston University]]. He holds the Chair of Vascular Biology and the 50th Anniversary Chair of [[Translational medicine|Translational Medicine]]. In addition, he is the KAU Distinguished Adjunct Professor at [[King Abdulaziz University|King AbdulAziz University]] and an Honorary Professor at the [[Jilin University|Jilin University Hospital]]. His main area of research is [[Angiogenesis|preeclampsia, angiogenesis]] and [[gaseous signalling molecules]]. In addition, Professor Ahmed established and leads the Aston Medical Research Institute, a university-wide multidisciplinary translational research entity at Aston University.{{fact}} |
||
Asif Ahmed is also the founder and the Chairman of |
Asif Ahmed is also the founder and the Chairman of MirZyme Therapeutics, a biopharmaceutical to be the first spin out company from Aston Medical School, focused on maternal and child health.{{fact}} |
||
==Education and Career== |
==Education and Career== |
||
Ahmed went to a local comprehensive [[Aylward School]] in North London and was subsequently educated at [[King's College London]] where he gained his undergraduate degree in [[Pharmacology]]. He was awarded a PhD for his work on platelet abnormalities in cardiopulmonary bypass surgery from [[University College London]] in 1989. |
Ahmed went to a local comprehensive [[Aylward School]] in North London and was subsequently educated at [[King's College London]] where he gained his undergraduate degree in [[Pharmacology]]. He was awarded a PhD for his work on platelet abnormalities in cardiopulmonary bypass surgery from [[University College London]] in 1989.{{fact}} |
||
From 1989-93 Professor Ahmed was a Postdoctoral Research Fellow at the [[University of Cambridge]]. From 1993-2010 he worked at [[The University of Birmingham]] being promoted to Professor of Reproductive Physiology in 1998. From 2009-2011 he was a Visiting Professor at [[Stanford University School of Medicine]]<ref>{{Cite web|url=https://www.timeshighereducation.com/appointments/422318.article|title=Times Higher Education|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. Between 2010 and 2012 he held the Inaugural [[Gustav Victor Rudolf Born|Gustav Born]] Chair of Vascular Biology<ref>{{Cite web|url=https://www.ed.ac.uk/alumni/services/news/news-archive/2013-news/gustavborn|title=University of Edinburgh|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> and was appointed as the Assistant Principal for International Postdoctoral Training at the [[University of Edinburgh]]<ref>{{Cite web|url=http://www.docs.sasg.ed.ac.uk/GaSP/Governance/Court/2011-2012/20120220AgendaandPapers.pdf|title=University of Edinburgh|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. Professor Ahmed joined [[Aston University]] as Pro-Vice-Chancellor for Health in October 2012.<ref>https://www.timeshighereducation.com/appointments/422318.article</ref> He was elected as a Fellow of the [[Royal Society of Biology]] in 2013. |
From 1989-93 Professor Ahmed was a Postdoctoral Research Fellow at the [[University of Cambridge]]. From 1993-2010 he worked at [[The University of Birmingham]] being promoted to Professor of Reproductive Physiology in 1998. From 2009-2011 he was a Visiting Professor at [[Stanford University School of Medicine]]<ref>{{Cite web|url=https://www.timeshighereducation.com/appointments/422318.article|title=Times Higher Education|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. Between 2010 and 2012 he held the Inaugural [[Gustav Victor Rudolf Born|Gustav Born]] Chair of Vascular Biology<ref>{{Cite web|url=https://www.ed.ac.uk/alumni/services/news/news-archive/2013-news/gustavborn|title=University of Edinburgh|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> and was appointed as the Assistant Principal for International Postdoctoral Training at the [[University of Edinburgh]]<ref>{{Cite web|url=http://www.docs.sasg.ed.ac.uk/GaSP/Governance/Court/2011-2012/20120220AgendaandPapers.pdf|title=University of Edinburgh|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>. Professor Ahmed joined [[Aston University]] as Pro-Vice-Chancellor for Health in October 2012.<ref>https://www.timeshighereducation.com/appointments/422318.article</ref> He was elected as a Fellow of the [[Royal Society of Biology]] in 2013. |
||
| Line 21: | Line 21: | ||
==Aston Medical School== |
==Aston Medical School== |
||
Ahmed conceived the concept of [[Aston Medical School]] and led in its development. The opening of Aston Medical School makes Birmingham the only UK city outside London to have two medical schools. Professor Ahmed developed a new model of medical education in the UK, with a focus on social mobility and business acumen, delivered at low cost to the public purse. |
Ahmed conceived the concept of [[Aston Medical School]] and led in its development. The opening of Aston Medical School makes Birmingham the only UK city outside London to have two medical schools. Professor Ahmed developed a new model of medical education in the UK, with a focus on social mobility and business acumen, delivered at low cost to the public purse.{{fact}} |
||
This model was recognized and endorsed by the Minister for Higher Education at the time, The RT Hon [[David Willetts]] <ref>http://www.aston.ac.uk/aston-medical-school/endorsements/</ref>. Aston Medical School opened in June 2014 and was awarded approval to admit undergraduate medical students by the [[General Medical Council]] in 2017. Aston Medical School is the fifth school at Aston University and will admit its first cohort of undergraduate medical students in to its [[MBChB]] course in September 2018 <ref>http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/</ref>. |
This model was recognized and endorsed by the Minister for Higher Education at the time, The RT Hon [[David Willetts]] <ref>http://www.aston.ac.uk/aston-medical-school/endorsements/</ref>. Aston Medical School opened in June 2014 and was awarded approval to admit undergraduate medical students by the [[General Medical Council]] in 2017. Aston Medical School is the fifth school at Aston University and will admit its first cohort of undergraduate medical students in to its [[MBChB]] course in September 2018 <ref>http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/</ref>. |
||
The MBChB course has a unique business leadership component linked to medicine which will be delivered in conjunction with Aston Business School |
The MBChB course has a unique business leadership component linked to medicine which will be delivered in conjunction with Aston Business School.<ref>http://www.aston.ac.uk/aston-medical-school/mbchb-medicine{{full}}</ref> |
||
The ethos of widening participation is supported through the Sir Doug Ellis Pathway to Healthcare programme<ref>http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/</ref> |
The ethos of widening participation is supported through the Sir Doug Ellis Pathway to Healthcare programme.<ref>http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/{{full}}</ref> The programme is named after Aston Villa FC Chairman [[Doug Ellis|Sir Doug Ellis]] who has financially supported the programme. |
||
In 2015, Aston Medical School started to offer MSc, PhD and CPD courses. |
In 2015, [[Aston Medical School]] started to offer MSc, PhD and CPD courses.{{fact}} |
||
==Research Interests== |
==Research Interests== |
||
Ahmed’s laboratory was amongst the first to signal the importance of vascular growth factors in pregnancy and pioneered the concept of angiogenic imbalance theory in [[preeclampsia]] in the mid-1990s<ref> |
Ahmed’s laboratory was amongst the first to signal the importance of vascular growth factors in pregnancy and pioneered the concept of angiogenic imbalance theory in [[preeclampsia]] in the mid-1990s.<ref name=pmid9194854>{{cite journal |pmid=9194854 }}</ref> |
||
In 2000, he discovered that the enzyme placental heme oxygenase (HO) which protects the human placenta against injury<ref> |
In 2000, he discovered that the enzyme placental heme oxygenase (HO) which protects the human placenta against injury<ref name=pmid10952020>{{cite journal |pmid=10952020 }}</ref> and went on to identify carbon monoxide (CO), the gaseous product of HO, as an inhibitor of anti-angiogenic proteins (soluble Flt-1 and soluble endoglin)<ref name=pmid17389265>{{cite journal |doi=10.1161/CIRCULATIONAHA.106.660134 }}</ref><ref name=pmid23704251>{{cite journal |doi=10.1161/CIRCULATIONAHA.113.001631 }}</ref> |
||
Soluble Flt-1, the natural anti-VEGF factor in circulation, is increasingly recognized as a major factor responsible for the clinical signs of preeclampsia. Professor Ahmed identified soluble Flt-1 as the single most important molecule responsible for the angiogenic imbalance in preeclampsia by demonstrating that the removal of soluble Flt-1 from preeclamptic samples restored angiogenic balance<ref>{{ |
Soluble Flt-1, the natural anti-VEGF factor in circulation, is increasingly recognized as a major factor responsible for the clinical signs of preeclampsia. Professor Ahmed identified soluble Flt-1 as the single most important molecule responsible for the angiogenic imbalance in preeclampsia by demonstrating that the removal of soluble Flt-1 from preeclamptic samples restored angiogenic balance<ref name=pmid15472115>{{cite journal |doi=10.1161/01.RES.0000147365.86159.f5 }}</ref> which was later confirmed in vivo by others.{{who}} |
||
The identification that increasing HO activity could provide protection against preeclampsia formed the basis for the world’s first randomized controlled clinical trial on statins in pregnancy, StAmP Trial<ref>{{Cite web|url=http://www.isrctn.com/ISRCTN23410175|title=Statins to Ameliorate early onset Pre-eclampsia|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref>{{Cite news|url=http://www.telegraph.co.uk/news/health/news/8464262/Heart-disease-drugs-could-treat-pregnant-women.html|title=Heart disease drugs could treat pregnant women|last=Beckford|first=Martin|date=2011-04-21|access-date=2018-01-15|language=en-GB|issn=0307-1235}}</ref><ref>{{Cite news|url=http://www.bbc.co.uk/news/uk-scotland-edinburgh-east-fife-13141834|title=Pregnancy trial to use heart drug|date=2011-04-20|work=BBC News|access-date=2018-01-15|language=en-GB}}</ref>. As of 2017, under Ahmed's leadership Aston Medical School had secured nearly £10million of external funding. |
The identification that increasing HO activity could provide protection against preeclampsia formed the basis for the world’s first randomized controlled clinical trial on statins in pregnancy, StAmP Trial<ref>{{Cite web|url=http://www.isrctn.com/ISRCTN23410175|title=Statins to Ameliorate early onset Pre-eclampsia|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref>{{Cite news|url=http://www.telegraph.co.uk/news/health/news/8464262/Heart-disease-drugs-could-treat-pregnant-women.html|title=Heart disease drugs could treat pregnant women|last=Beckford|first=Martin|date=2011-04-21|access-date=2018-01-15|language=en-GB|issn=0307-1235}}</ref><ref>{{Cite news|url=http://www.bbc.co.uk/news/uk-scotland-edinburgh-east-fife-13141834|title=Pregnancy trial to use heart drug|date=2011-04-20|work=BBC News|access-date=2018-01-15|language=en-GB}}</ref>. As of 2017, under Ahmed's leadership Aston Medical School had secured nearly £10million of external funding. |
||
==Other Interests== |
==Other Interests== |
||
Ahmed is a published poet and loves hiking. |
Ahmed is a published poet and loves hiking.{{fact}} |
||
==References== |
==References== |
||
Revision as of 13:44, 20 January 2018
 |
Asif Ahmed | |
|---|---|
 | |
| Alma mater | King's College London University College London |
Asif Ahmed FRSB (born 1st June 1960) is a British vascular and obstetric scientist and an entrepreneur[1]. He is responsible for founding Aston Medical School, the second medical school to be established in the city of Birmingham after 200 years. Aston Medical School has social mobility and leadership at the core of its model without compromising entry standards.[2] Ahmed's discoveries and his disrupitve approach have led to new clinical trials designed to treat the deadliest maternal hypertensive disorder, preeclampsia. He has a longstanding interest in the mechanisms of vascular endothelial growth factor signalling, endothelial cell protection and has developed new strategies for preventing preeclampsia.[3] He is widely recognized as the first person to propose and initiate the first clinical trial on statins to ameliorate sever preeclampsia.[4]
Ahmed is the inaugural Executive Dean of Aston Medical School and Pro-Vice-Chancellor at Aston University. He holds the Chair of Vascular Biology and the 50th Anniversary Chair of Translational Medicine. In addition, he is the KAU Distinguished Adjunct Professor at King AbdulAziz University and an Honorary Professor at the Jilin University Hospital. His main area of research is preeclampsia, angiogenesis and gaseous signalling molecules. In addition, Professor Ahmed established and leads the Aston Medical Research Institute, a university-wide multidisciplinary translational research entity at Aston University.[citation needed]
Asif Ahmed is also the founder and the Chairman of MirZyme Therapeutics, a biopharmaceutical to be the first spin out company from Aston Medical School, focused on maternal and child health.[citation needed]
Education and Career
Ahmed went to a local comprehensive Aylward School in North London and was subsequently educated at King's College London where he gained his undergraduate degree in Pharmacology. He was awarded a PhD for his work on platelet abnormalities in cardiopulmonary bypass surgery from University College London in 1989.[citation needed]
From 1989-93 Professor Ahmed was a Postdoctoral Research Fellow at the University of Cambridge. From 1993-2010 he worked at The University of Birmingham being promoted to Professor of Reproductive Physiology in 1998. From 2009-2011 he was a Visiting Professor at Stanford University School of Medicine[5]. Between 2010 and 2012 he held the Inaugural Gustav Born Chair of Vascular Biology[6] and was appointed as the Assistant Principal for International Postdoctoral Training at the University of Edinburgh[7]. Professor Ahmed joined Aston University as Pro-Vice-Chancellor for Health in October 2012.[8] He was elected as a Fellow of the Royal Society of Biology in 2013.
Aston Medical School
Ahmed conceived the concept of Aston Medical School and led in its development. The opening of Aston Medical School makes Birmingham the only UK city outside London to have two medical schools. Professor Ahmed developed a new model of medical education in the UK, with a focus on social mobility and business acumen, delivered at low cost to the public purse.[citation needed]
This model was recognized and endorsed by the Minister for Higher Education at the time, The RT Hon David Willetts [9]. Aston Medical School opened in June 2014 and was awarded approval to admit undergraduate medical students by the General Medical Council in 2017. Aston Medical School is the fifth school at Aston University and will admit its first cohort of undergraduate medical students in to its MBChB course in September 2018 [10].
The MBChB course has a unique business leadership component linked to medicine which will be delivered in conjunction with Aston Business School.[11]
The ethos of widening participation is supported through the Sir Doug Ellis Pathway to Healthcare programme.[12] The programme is named after Aston Villa FC Chairman Sir Doug Ellis who has financially supported the programme.
In 2015, Aston Medical School started to offer MSc, PhD and CPD courses.[citation needed]
Research Interests
Ahmed’s laboratory was amongst the first to signal the importance of vascular growth factors in pregnancy and pioneered the concept of angiogenic imbalance theory in preeclampsia in the mid-1990s.[13]
In 2000, he discovered that the enzyme placental heme oxygenase (HO) which protects the human placenta against injury[14] and went on to identify carbon monoxide (CO), the gaseous product of HO, as an inhibitor of anti-angiogenic proteins (soluble Flt-1 and soluble endoglin)[15][16]
Soluble Flt-1, the natural anti-VEGF factor in circulation, is increasingly recognized as a major factor responsible for the clinical signs of preeclampsia. Professor Ahmed identified soluble Flt-1 as the single most important molecule responsible for the angiogenic imbalance in preeclampsia by demonstrating that the removal of soluble Flt-1 from preeclamptic samples restored angiogenic balance[17] which was later confirmed in vivo by others.[who?]
The identification that increasing HO activity could provide protection against preeclampsia formed the basis for the world’s first randomized controlled clinical trial on statins in pregnancy, StAmP Trial[18][19][20]. As of 2017, under Ahmed's leadership Aston Medical School had secured nearly £10million of external funding.
Other Interests
Ahmed is a published poet and loves hiking.[citation needed]
References
- ^ "Birmingham Post".
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ http://www.aston.ac.uk/aston-medical-school/
- ^ . PMID 27873232.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1186/ISRCTN23410175.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help)CS1 maint: unflagged free DOI (link) - ^ "Times Higher Education".
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ "University of Edinburgh".
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ "University of Edinburgh" (PDF).
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ https://www.timeshighereducation.com/appointments/422318.article
- ^ http://www.aston.ac.uk/aston-medical-school/endorsements/
- ^ http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/
- ^ http://www.aston.ac.uk/aston-medical-school/mbchb-medicine[full citation needed]
- ^ http://www.aston.ac.uk/aston-medical-school/mbchb-medicine/[full citation needed]
- ^ . PMID 9194854.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . PMID 10952020.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1161/CIRCULATIONAHA.106.660134.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1161/CIRCULATIONAHA.113.001631.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1161/01.RES.0000147365.86159.f5.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ "Statins to Ameliorate early onset Pre-eclampsia".
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ Beckford, Martin (2011-04-21). "Heart disease drugs could treat pregnant women". ISSN 0307-1235. Retrieved 2018-01-15.
- ^ "Pregnancy trial to use heart drug". BBC News. 2011-04-20. Retrieved 2018-01-15.